Abstract Background The Ad26. COV2. S vaccine is a recombinant, replication-incompetent
human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

ABSTRACT BACKGROUND The ongoing coronavirus disease (COVID)-19 pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be …

Abstract Background The Ad26. COV2. S vaccine was highly effective against severe–
critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase …

Background Despite the availability of effective vaccines against COVID-19, booster
vaccinations are needed to maintain vaccine-induced protection against variant strains and …

Importance Control of the global COVID-19 pandemic will require the development and
deployment of safe and effective vaccines. Objective To evaluate the immunogenicity of the …

Background A vaccine to protect against COVID-19 is urgently needed. We aimed to assess
the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) …

Importance Continuous assessment of the effectiveness and safety of the US Food and Drug
Administration–authorized SARS-CoV-2 vaccines is critical to amplify transparency, build …

Previously we have shown that a single dose of recombinant adenovirus serotype 26 (Ad26)
vaccine expressing a prefusion stabilized SARS-CoV-2 spike antigen (Ad26. COV2. S) is …

Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole
virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist …